Aim:To develop a mucosal inactivated vaccines for Newcastle disease (ND) and H9N2 viruses to protect against these viruses at sites of infections through mucosal immunity.Materials and Methods:In this study, we prepared two new formulations for mucosal bivalent inactivated vaccine formulations for Newcastle and Avian Influenza (H9N2) based on the use of nanoparticles and polymer adjuvants. The prepared vaccines were delivered via intranasal and spray routes of administration in specific pathogen-free chickens. Cell-mediated and humoral immune response was measured as well as challenge trial was carried out. In addition, ISA71 water in oil was also evaluated.Results:Our results showed that the use of spray route as vaccination delivery method of polymer and nanoparticles Montanide™ adjuvants revealed that it enhanced the cell mediated immune response as indicated by phagocytic activity, gamma interferon and interleukin 6 responses and induced protection against challenge with Newcastle and Avian Influenza (H9N2) viruses.Conclusion:The results of this study demonstrate the potentiality of polymer compared to nanoparticles adjuvantes when used via spray route. Mass application of such vaccines will add value to improve the vaccination strategies against ND virus and Avian influenza viruses.

Oncogenic potential of Blastocystis species have been predicted on reporting the enhanced proliferation of human colorectal cancer cells by the parasite solubilized antigen in vitro, and the enhanced drug-induced carcinogenesis by infection in vivo. The present study is the first to investigate some phenotypic characters, namely the surface ultrastructure, protein profiles and protease activity of Blastocystis sp. isolated from three different clinical groups: colorectal carcinoma (CRC) patients, symptomatic and asymptomatic infected persons. Under SEM, all CRC Blastocystis sp. isolates had a very rough intensely folded surface in comparison to the less rough and completely smooth surface of all symptomatic and asymptomatic Blastocystis sp. Non-CRC isolates, respectively. Under reducing conditions, the sodium dodecyl sulfate-polyacrylamide gel electrophoresis had shown a significant presence of 2 protein bands of 230 and 32 KDa in 42.9% of Blastocystis sp. CRC isolates with their complete absence from Non-CRC isolates. While using non-reducing condition with the incorporation of gelatin in the gel to study the protease activity of the parasite, no significant difference existed between isolates of the three groups. In conclusion, the significant difference in surface ultrastructure and in protein profiles exists between Blastocystis sp. of CRC and Non-CRC isolates. These differences might be either secondary to the altered gut environment in the presence of CRC or are indicators of a different pathogenic potential of the parasite isolates inducing malignancy.

No abstract

Background and Aim: One strategy that can be used to stabilize vaccines is to convert them into a dry powder. This can protect the integrity of the active ingredients as well as vaccine antigenicity during manufacture, storage, and transport. This study highlights the potent adjuvant activity of Carbopol® when used alone to stabilize live-attenuated Newcastle disease virus (NDV) vaccines or when used in a formulation together with skimmed milk. Tolerability and potency of these formulations were compared with those obtained from other local live NDV vaccines produced locally by the Veterinary Serum and Vaccine Research Institute. Materials and Methods: We evaluated the cellular and humoral immune responses to a locally prepared, live-attenuated LaSota virus vaccine. Vaccine formulations were stabilized with Carbopol® 940 alone or in combination with skimmed milk. Results: Our results indicate that the use of Carbopol® 940 alone to stabilize a live-attenuated LaSota vaccine resulted in enhanced cellular and humoral immunity. The antibody titer was prolonged through the 6th week post-vaccination (5.0 log2). Full (100%) protection was observed in response to challenge with very virulent NDV at day 21 after vaccination; there were no clinical signs or lesions on examination. Addition of Carbopol® 940 to the live-attenuated vaccine formulation resulted in a more compact, stable, and high-quality lyophilized cake after freeze-dried lyophilization compared with that produced by stabilization with skimmed milk alone. Conclusion: Our data suggest that Carbopol® 940 may improve clinical responses to live-attenuated vaccines.